Skip To Main Content
Barnaby Hunt MSc on Muck Rack

Barnaby Hunt MSc

As seen in: Color Research & Application
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barnaby Hunt

Contact Barnaby Hunt, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Evaluating the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real‐world clinical evidence - Raya - - Diabetes, Obesity and Metabolism - Wiley Online Library

|
By Barnaby Hunt MSc, Pedro Mezquita Raya, Barnaby Hunt, Virginia Martin
| Color Research & Application Verified
Abstract Aim To evaluate the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus comparator regimens for type 2 diabetes in Spain, based on real‐world evidence. Materials and methods Clinical data were taken from the European Xultophy Treatment Retrospective Audit (EXTRA) real‐world evidence study in which patients failing to meet glycaemic targets were switched to IDegLira.
Open in Who Shared Issue with article?

Evaluation of the Long‐Term Cost‐Effectiveness of Once‐Weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK

|
By Barnaby Hunt MSc, Adie Viljoen, Christina Stentoft Hoxer, Pierre Johansen
| Color Research & Application Verified
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are an appealing glucose‐lowering therapy for people with type 2 diabetes mellitus (T2DM), since they also reduce body weight, and are associated with low rates of hypoglycaemia.
Open in Who Shared Issue with article?

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A short‐term cost‐effectiveness analysis in the UK setting - Drummond - - Diabet

|
By Barnaby Hunt MSc, Russell Drummond, Samuel Malkin, Michelle Du Preez
| Color Research & Application Verified
To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK. A Microsoft Excel model was used to evaluate the cost‐utility of IDegLira versus BBT over a 1‐year time horizon.
Open in Who Shared Issue with article?
See all 4 articles